Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
News|Videos|May 22, 2023
Evolution of Pharmacological Treatments at the 2023 APA Annual Meeting
Author(s)John J. Miller, MD
An inside look at what treatments are being discussed in San Francisco...
Advertisement
CONFERENCE REPORTER
What exciting treatments are being discussed at the APA Annual meeting this year? Psychiatric Times Editor-in-Chief, John J. Miller, MD, gives an overview.
What new treatments are you interested in? Let us know at
Dr Miller is Medical Director, Brain Health, Exeter, New Hampshire; Editor in Chief, Psychiatric Times; Staff Psychiatrist, Seacoast Mental Health Center, Exeter; Consulting Psychiatrist, Exeter Hospital, Exeter; Consulting Psychiatrist, Insight Meditation Society, Barre, Massachusetts.
Advertisement
Related to this article
Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Pramipexole was associated with improvement in anhedonia and apathy, and with increased physical activity in patients with mood disorders, in a placebo-controlled trial that measured both behavioral and neurophysiologic change.
Much of what we call "treatment-resistant" depression may be mismatched, not resistant. A psychiatrist makes the case for trading the failed-drug tally for a difficult-to-treat framework clinicians can act on Monday morning.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Vol 43, Issue 9 - Interactive
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
Debunking the Top 10 Misleading Claims About Antidepressants
4
New Adult ADHD Guidelines: What Resources Are Coming Soon
5